Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors

about

Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors

Item

http://www.wikidata.org/entity/Q58759036

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2018

@uk

name

Design, synthesis, and screeni ...... carcinomaas VEGFR-2Inhibitors

@en

Design, synthesis, and screeni ...... carcinomaas VEGFR-2Inhibitors

@nl

type

Item

label

Design, synthesis, and screeni ...... carcinomaas VEGFR-2Inhibitors

@en

Design, synthesis, and screeni ...... carcinomaas VEGFR-2Inhibitors

@nl

prefLabel

Design, synthesis, and screeni ...... carcinomaas VEGFR-2Inhibitors

@en

Design, synthesis, and screeni ...... carcinomaas VEGFR-2Inhibitors

@nl

P1476

Design, synthesis, and screeni ...... carcinomaas VEGFR-2Inhibitors

@en

P2093

Mohammed K AbdElhameid

http://www.w3.org/2001/XMLSchema#string

Muhammad Al-Shorbagy

http://www.w3.org/2001/XMLSchema#string

P2860

Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics

Receptor tyrosine kinase signalling as a target for cancer intervention strategies

New colorimetric cytotoxicity assay for anticancer-drug screening

Rational design of inhibitors that bind to inactive kinase conformations

An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents

A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe.

Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.

Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.

P304

1472-1493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14756366.2018.1503654

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Manal R Mohammed

Ahmed T Negmeldin

Madlen B Labib

P577

2018-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30191744

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

drug discovery

P932

6136361

http://www.w3.org/2001/XMLSchema#string